Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus

Inclusion Criteria:

* Karnofsky performance status of 50-100%
* Life expectancy greater than 5 years
* Hematopoietic, Hepatic and Renal lab clearance
* Previous endoscopy with histological confirmation of LGD or HGD within BE
* For Group 2, deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney or liver disease; or refusal of surgical intervention after a thorough unbiased discussion of surgery.
* For Group 2, endoscopic ultrasound (EUS) evaluation demonstrating no evidence of invasion or metastatic lymph node involvement (T0N0M0 by EUS).

Exclusion Criteria:

* Pregnant, not practicing adequate contraception, intending to become pregnant, or lactating at any time during the study (approximately 2 years).
* Esophageal stricture preventing passage of endoscope or catheter.
* Active esophagitis
* EMR performed less than 8 weeks prior to CSA treatment.
* EMR performed on greater than 90% circumference of any area of the esophagus.
* Any previous esophageal surgery, except fundoplication without complications.
* Known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines.
* Concurrent enrollment in an investigational drug or device trial that clinically interferes with the LCS Dysplasia endpoints.
* Psychiatric or other illness deemed by the investigator as an inability to comply with this protocol.
* Medically unfit or other contraindication to tolerate upper endoscopy.
* Inability to tolerate therapy with a proton pump inhibitor (PPI).
* Refusal or inability to give consent.
* Other active malignancy (except nonmelanoma skin cancer or another cancer for which patient is deemed disease-free).
* Concurrent chemotherapy.
* Prior radiation therapy which involved the esophagus.
* Prior adenocarcinoma involving the esophagus or stomach.
* Prior or concurrent ablation therapy including, but not limited to, photodynamic therapy, multipolar electro coagulation, argon plasma coagulation, laser treatment, radio frequency, etc.